Barclays analyst Balaji Prasad lowered the firm’s price target on Ligand Pharmaceuticals to $110 from $120 and keeps an Overweight rating on the shares ahead of the Q2 results.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LGND:
- Ligand offers to acquire Novan for $15M in cash, $15M in financing
- Novan to sell substantially all assets for $15M, files for Chapter 11 protection
- Biotech Alert: Searches spiking for these stocks today
Questions or Comments about the article? Write to editor@tipranks.com